George Geroulakos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
George Geroulakos has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Andreas M. Lazaris
National Kapodistrian University of Athens- Medical School, Haidari Athens, Greece
5 shared publications - Anastasios Papapetrou
Department of Vascular Surgery, “KAT” General Hospital of Athens, 14561 Kifisia, Greece
2 shared publications - Angelos Megalopoulos
Department of Vascular Surgery, “George Papanikolaou” General Hospital of Thessaloniki, 57010 Exochi, Greece
2 shared publications - Christiana Anastasiadou
Division of Vascular Surgery, First Department of Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Papageorgiou General Hospital, 56403 Thessaloniki, Greece
2 shared publications - Christopher Richard Lattimer
Josef Pflug Vascular Laboratory, West London Vascular and Interventional Centre, Ealing Hospital & Imperial College, London, UK
2 shared publications - Christos D. Liapis
Department of Vascular and Endovascular Surgery Athens Medical Center Athens Greece
2 shared publications
Latest Publications
- Open Access
- 11 August 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (8) , 126
Effect of Cilostazol in the Expression of Biomarkers and Neurological Outcome Following Experimentally Induced Cerebrovascular Accident—Experimental Protocol
Objective: Several strategies have been described for stroke prevention, and the most commonly used medication is aspirin. Cilostazol, which is a substance with a pleiotropic effect, is still not well investigated. In this study, we aimed to delineate the effects of mono- and combinatorial pre-treatment upon neurological status and biomarkers, namely protein S100b, GFAP, procalcitonin, and galectin-3, following stroke. Methods: Twelve-week-old Sprague–Dawley rats were randomly assigned to four groups, each containing six rats: control group (normal saline), cilostazol group (30 mg/kg/daily), aspirin group (10 mg/kg/daily), and aspirin/cilostazol group. Each substance was administered by gavage for four weeks. All animals were subjected to cerebral ischemia for 2 h using intraluminal middle cerebral artery occlusion. A neurological examination was performed, serum concentrations of biomarkers were determined, and the animals were then sacrificed. Results: All treatment groups exhibited variations in the severity of immediate neurological presentation. Unlike the control group, where all rats presented with severe focal neurology or mortality, most rats in the treatment groups displayed no to moderate focal neurology. Moreover, the aspirin/cilostazol group consistently exhibited significantly lower levels in the studied biomarkers compared to other groups. Conclusions: Co-administration of cilostazol and aspirin significantly ameliorates the immediate expression of the studied biomarkers. Further large-scale studies are needed to investigate the effect of combined therapy for primary and secondary prevention of stroke, using not only serum biomarkers but other specific clinical and laboratory endpoints.
- 11 August 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (8) , 126
Open AccessEffect of Cilostazol in the Expression of Biomarkers and Neurological Outcome Following Experimentally Induced Cerebrovascular Accident—Experimental Protocol
Objective: Several strategies have been described for stroke prevention, and the most commonly used medication is aspirin. Cilostazol, which is a substance with a pleiotropic effect, is still not well investigated. In this study, we aimed to delineate the effects of mono- and combinatorial pre-treatment upon neurological status and biomarkers, namely protein S100b, GFAP, procalcitonin, and galectin-3, following stroke. Methods: Twelve-week-old Sprague–Dawley rats were randomly assigned to four groups, each containing six rats: control group (normal saline), cilostazol group (30 mg/kg/daily), aspirin group (10 mg/kg/daily), and aspirin/cilostazol group. Each substance was administered by gavage for four weeks. All animals were subjected to cerebral ischemia for 2 h using intraluminal middle cerebral artery occlusion. A neurological examination was performed, serum concentrations of biomarkers were determined, and the animals were then sacrificed. Results: All treatment groups exhibited variations in the severity of immediate neurological presentation. Unlike the control group, where all rats presented with severe focal neurology or mortality, most rats in the treatment groups displayed no to moderate focal neurology. Moreover, the aspirin/cilostazol group consistently exhibited significantly lower levels in the studied biomarkers compared to other groups. Conclusions: Co-administration of cilostazol and aspirin significantly ameliorates the immediate expression of the studied biomarkers. Further large-scale studies are needed to investigate the effect of combined therapy for primary and secondary prevention of stroke, using not only serum biomarkers but other specific clinical and laboratory endpoints.
- Open Access
- 28 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 69
Effect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study
Objective: The contralateral hippocampus, a critical region for cognitive function, is often overlooked in everyday clinical practice and stroke research. This study aimed to evaluate the effect of specific antiplatelet agents on the hippocampus (ipsilateral and contralateral) during the hyperacute phase of stroke. Materials and Methods: Twelve-week-old rats were randomly assigned to four groups, each containing six rats: a cilostazol group, an aspirin group, an aspirin plus cilostazol group, and a control group. Each substance was administered for four weeks. Permanent brain ischemia was induced over 2 h using intraluminal middle cerebral artery occlusion. A neurologic examination was conducted, followed by euthanasia and histological examination of the CA1 hippocampal region. The hematoxylin and eosin stain was used to assess the total number of intact neuronal cell bodies and pyknotic nuclei, an indicator of early irreversible neuronal injury. Results: In the ipsilateral hippocampus, monotherapy with either aspirin or cilostazol significantly reduced pyknotic nuclei compared with the control group (p = 0.0016 and p = 0.0165, respectively). However, combination therapy showed no significant difference from the controls (p = 0.2375). In the contralateral hippocampus, cilostazol monotherapy demonstrated significantly reduced pyknotic nuclei (p = 0.0098), whereas aspirin monotherapy and combination therapy did not (p = 0.1009 and p = 0.9999, respectively). A cumulative analysis of both hemispheres revealed that monotherapy with aspirin or cilostazol markedly reduced injury markers (p = 0.0002 and p = 0.0001, respectively), whereas combined therapy revealed no significant benefit (p = 0.1984). A neurological assessment indicated that the most severe deficits were in the combination therapy group. Conclusions: To the best of our knowledge, this is the first study to compare acute histopathological changes in the affected and unaffected hippocampus after a stroke in a rat model. Dual antiplatelet therapy resulted in worse outcomes (histopathological and neurological) than monotherapy.
- 28 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 69
Open AccessEffect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study
Objective: The contralateral hippocampus, a critical region for cognitive function, is often overlooked in everyday clinical practice and stroke research. This study aimed to evaluate the effect of specific antiplatelet agents on the hippocampus (ipsilateral and contralateral) during the hyperacute phase of stroke. Materials and Methods: Twelve-week-old rats were randomly assigned to four groups, each containing six rats: a cilostazol group, an aspirin group, an aspirin plus cilostazol group, and a control group. Each substance was administered for four weeks. Permanent brain ischemia was induced over 2 h using intraluminal middle cerebral artery occlusion. A neurologic examination was conducted, followed by euthanasia and histological examination of the CA1 hippocampal region. The hematoxylin and eosin stain was used to assess the total number of intact neuronal cell bodies and pyknotic nuclei, an indicator of early irreversible neuronal injury. Results: In the ipsilateral hippocampus, monotherapy with either aspirin or cilostazol significantly reduced pyknotic nuclei compared with the control group (p = 0.0016 and p = 0.0165, respectively). However, combination therapy showed no significant difference from the controls (p = 0.2375). In the contralateral hippocampus, cilostazol monotherapy demonstrated significantly reduced pyknotic nuclei (p = 0.0098), whereas aspirin monotherapy and combination therapy did not (p = 0.1009 and p = 0.9999, respectively). A cumulative analysis of both hemispheres revealed that monotherapy with aspirin or cilostazol markedly reduced injury markers (p = 0.0002 and p = 0.0001, respectively), whereas combined therapy revealed no significant benefit (p = 0.1984). A neurological assessment indicated that the most severe deficits were in the combination therapy group. Conclusions: To the best of our knowledge, this is the first study to compare acute histopathological changes in the affected and unaffected hippocampus after a stroke in a rat model. Dual antiplatelet therapy resulted in worse outcomes (histopathological and neurological) than monotherapy.
- 30 April 2024
- Published by Springer Nature
- p. 823-826
Primary Subclavian Vein Thrombosis (Paget–Schroetter Syndrome)
- 30 April 2024
- Published by Springer Nature
- p. 823-826
Primary Subclavian Vein Thrombosis (Paget–Schroetter Syndrome)
- Open Access
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1310
Treatment with Umbilical Cord Blood Platelet Lysate Gel Improves Healing of Diabetic Foot Ulcer
Background: This study was conducted to examine the hypothesis that umbilical cord blood platelet lysate (UCB-PL) gel has a significant impact on the healing rate of DFU. Μethods: In this open-labeled, randomized controlled trial, 110 patients were randomized to treatment with UCB-PL gel (UCB-PL group, n = 52) every three days for one month or dressing with normal saline (control group, n = 58). All participants were followed up for 20 weeks post treatment. Ulcer surface area was assessed with the imitoMeasure application at two, four, and six weeks, and two, four and six months. This study’s main outcome was the reduction in ulcer size over the six-month study period. Results: The mean ulcer area at baseline was 4.1 cm2 in the UCB-PL group and 1.7 cm2 in the control group. At six months post treatment, patients on the UCB-PL treatment displayed a significant reduction in ulcer size compared to baseline 0.12 (0–8.16) in contrast to a more modest change in the control group 1.05 (0–24.7). The ulcer area was decreased at the end of the study in 40 patients (97.6%) in the UCB-PL group and 27 (73%) in the control group (Fisher’s p = 0.002). Conclusions: The application of UCB-PL gel in DFU resulted in a significant reduction in ulcer size compared to regular saline dressing.
- 26 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1310
Open AccessTreatment with Umbilical Cord Blood Platelet Lysate Gel Improves Healing of Diabetic Foot Ulcer
Background: This study was conducted to examine the hypothesis that umbilical cord blood platelet lysate (UCB-PL) gel has a significant impact on the healing rate of DFU. Μethods: In this open-labeled, randomized controlled trial, 110 patients were randomized to treatment with UCB-PL gel (UCB-PL group, n = 52) every three days for one month or dressing with normal saline (control group, n = 58). All participants were followed up for 20 weeks post treatment. Ulcer surface area was assessed with the imitoMeasure application at two, four, and six weeks, and two, four and six months. This study’s main outcome was the reduction in ulcer size over the six-month study period. Results: The mean ulcer area at baseline was 4.1 cm2 in the UCB-PL group and 1.7 cm2 in the control group. At six months post treatment, patients on the UCB-PL treatment displayed a significant reduction in ulcer size compared to baseline 0.12 (0–8.16) in contrast to a more modest change in the control group 1.05 (0–24.7). The ulcer area was decreased at the end of the study in 40 patients (97.6%) in the UCB-PL group and 27 (73%) in the control group (Fisher’s p = 0.002). Conclusions: The application of UCB-PL gel in DFU resulted in a significant reduction in ulcer size compared to regular saline dressing.
- 12 October 2023
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 67 (1) , 3-5
The 2024 ESVS Guidelines on Lower Limb Peripheral Arterial Disease: A Step Forward
- 12 October 2023
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 67 (1) , 3-5
The 2024 ESVS Guidelines on Lower Limb Peripheral Arterial Disease: A Step Forward
- 1 July 2020
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 72 (1) , 373-374
Doing the right thing for the right reason when treating ruptured abdominal aortic aneurysms in the COVID-19 era
- 1 July 2020
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 72 (1) , 373-374
Doing the right thing for the right reason when treating ruptured abdominal aortic aneurysms in the COVID-19 era
- Open Access
- 11 May 2020
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 29 (2) , 75-77
A reappraisal of thrombolysis in primary deep vein thrombosis of upper extremities: Be conservative
Thrombolysis is increasingly used in academic centres as first line management in patients who present within the first two weeks of the index event and upper extremity primary deep vein thrombosis (UEDVT). The purpose of this report is to establish whether this approach is evidence based. A review of the recent literature showed that thrombolysis should be offered to a small number of young and active patients with severe acute symptoms, who are very concerned about developing post-thrombotic syndrome. The majority of the patients can still be treated with anticoagulation alone as there is only limited evidence on the merits of thrombolysis for the initial management of patients with UEDVT.
- 11 May 2020
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 29 (2) , 75-77
Open AccessA reappraisal of thrombolysis in primary deep vein thrombosis of upper extremities: Be conservative
Thrombolysis is increasingly used in academic centres as first line management in patients who present within the first two weeks of the index event and upper extremity primary deep vein thrombosis (UEDVT). The purpose of this report is to establish whether this approach is evidence based. A review of the recent literature showed that thrombolysis should be offered to a small number of young and active patients with severe acute symptoms, who are very concerned about developing post-thrombotic syndrome. The majority of the patients can still be treated with anticoagulation alone as there is only limited evidence on the merits of thrombolysis for the initial management of patients with UEDVT.
- 1 May 2019
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 7 (3) , 315-316
Ablate early the superficial reflux but don't neglect deep reflux or obstruction
- 1 May 2019
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 7 (3) , 315-316
Ablate early the superficial reflux but don't neglect deep reflux or obstruction
- Open Access
- 7 January 2019
- Published by SAGE Publications in Angiology
- Vol. 70 (6) , 477-478
Repeat Endovascular Intervention Versus Lower Extremity Bypass for Failed Previous Endovascular Intervention
- 7 January 2019
- Published by SAGE Publications in Angiology
- Vol. 70 (6) , 477-478
Open AccessRepeat Endovascular Intervention Versus Lower Extremity Bypass for Failed Previous Endovascular Intervention
- 10 December 2017
- Published by Springer Nature
- p. 87-101
Open Surgical Treatment of Superficial Reflux